Beginning in 2003 a group of leading design engineers worked vigorously to optimise the performance of UVGI and in doing so created Medixair. Leading members of the academic and scientific community have subsequently assessed and approved the theoretical basis of the technology and the product is now the subject of several international patents.
Testing of Medixair has taken place at all levels of product development, embracing the following spectrum of analysis:
A range of trials carried out by an independent UKAS accredited laboratory - Microsearch Laboratories.
The technical appraisal and assessment for Medixair has been carried out by Europe’s Largest Science and Technology Organisation - QinetiQ.
A number of successful clinical trials have been undertaken within the NHS acute hospital and, during 2009, the range and depth of these trial is being expanded.
Medixair is distributed by a number of sector specialists around the world, including GE Healthcare in the acute hospital sector. Contact us to arrange to meet your specialist partner.
Medixair is achieving sales around the world and in multiple market sectors.
This is however not the end of our journey. As a learning organisation we are committed to identifying high performing global partners and new applications for Medixair.